🇺🇸 FDA
Pipeline program

NPS 1776 (800 mg)

CL1776-005

Phase 2 small_molecule completed

Quick answer

NPS 1776 (800 mg) for Migraine Headache is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Migraine Headache
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials